Clinical Trial Update: An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

View source ↗

Summary

An open-label, proof-of-concept study evaluating the effects of dalfampridine withdrawal on gait and balance in people with multiple sclerosis. The trial is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dalfampridine (dalfampridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Multiple Sclerosis | Status: COMPLETED | Results posted: 2013-10-14